One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The complex balance of PI3K inhibition
H. Vanacker, P.A. Cassier, T. Bachelot
doi : 10.1016/j.annonc.2020.10.597
Volume 32, Issue 2, February 2021, Pages 127-128
SOLAR1s: alpelisib returns to earth?
A. Matikas, T. Foukakis
doi : 10.1016/j.annonc.2020.12.003
Volume 32, Issue 2, February 2021, Pages 129-132
Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting
F.X. Real, J.T. Siveke
doi : 10.1016/j.annonc.2020.11.012
Volume 32, Issue 2, February 2021, Pages 133-135
How often do highly promising cancer biology discoveries translate into effective treatments?
R.S. Waters, V. Prasad
doi : 10.1016/j.annonc.2020.10.484
Volume 32, Issue 2, February 2021, Pages 136-138
The ESMO-EANO clinical practice guidelines for neurological and vascular complications of primary and secondary brain tumours: a valuable tool for clinicians
J.M. Sepúlveda-Sánchez, A. Pérez-Núñez
doi : 10.1016/j.annonc.2020.12.005
Volume 32, Issue 2, February 2021, Pages 139-141
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Fenaux, D. Haase, V. Santini, G.F. Sanz, ... U. Mey
doi : 10.1016/j.annonc.2020.11.002
Volume 32, Issue 2, February 2021, Pages 142-156
Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
M.E. Lacouture, V. Sibaud, P.A. Gerber, C. van den Hurk, ... K. Jordan
doi : 10.1016/j.annonc.2020.11.005
Volume 32, Issue 2, February 2021, Pages 157-170
Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up
P. Roth, A. Pace, E. Le Rhun, M. Weller, ... M. Preusser
doi : 10.1016/j.annonc.2020.11.003
Volume 32, Issue 2, February 2021, Pages 171-182
Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine
R. Casolino, C. Braconi, G. Malleo, S. Paiella, ... T. Golan
doi : 10.1016/j.annonc.2020.11.013
Volume 32, Issue 2, February 2021, Pages 183-196
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S. Dent, J. Cortés, Y.-H. Im, V. Diéras, ... W. Jacot
doi : 10.1016/j.annonc.2020.10.596
Volume 32, Issue 2, February 2021, Pages 197-207
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
F. André, E.M. Ciruelos, D. Juric, S. Loibl, ... H.S. Rugo
doi : 10.1016/j.annonc.2020.11.011
Volume 32, Issue 2, February 2021, Pages 208-217
Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial
B. Xu, T. Sun, Q. Zhang, P. Zhang, ... R. Qiu
doi : 10.1016/j.annonc.2020.10.600
Volume 32, Issue 2, February 2021, Pages 218-228
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
M.J.M. Magbanua, L.B. Swigart, H.-T. Wu, G.L. Hirst, ... L.J. van ‘t Veer
doi : 10.1016/j.annonc.2020.11.007
Volume 32, Issue 2, February 2021, Pages 229-239
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
H.P. Eikesdal, S. Yndestad, A. Elzawahry, A. Llop-Guevara, ... P.E. Lønning
doi : 10.1016/j.annonc.2020.11.009
Volume 32, Issue 2, February 2021, Pages 240-249
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
R. Nicolle, O. Gayet, P. Duconseil, C. Vanbrugghe, ... N.J. Dusetti
doi : 10.1016/j.annonc.2020.10.601
Volume 32, Issue 2, February 2021, Pages 250-260
Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
V. Subbiah, T. Shen, S.S. Terzyan, X. Liu, ... J. Wu
doi : 10.1016/j.annonc.2020.10.599
Volume 32, Issue 2, February 2021, Pages 261-268
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
G. Saturno, F. Lopes, I. Niculescu-Duvaz, D. Niculescu-Duvaz, ... C. Springer
doi : 10.1016/j.annonc.2020.10.483
Volume 32, Issue 2, February 2021, Pages 269-278
Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?
K. Khaddour, M. Ansstas, J. Visconti, G. Ansstas
doi : 10.1016/j.annonc.2020.10.602
Volume 32, Issue 2, February 2021, Pages 279-280
Ongoing partial response at 6 months to olaparib for metastatic melanoma with somatic PALB2 mutation after failure of immunotherapy: a case report
B. Lau, A.M. Menzies, A.M. Joshua
doi : 10.1016/j.annonc.2020.11.006
Volume 32, Issue 2, February 2021, Pages 280-282
Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review
S.N. Deftereos, D. Georgonikou
doi : 10.1016/j.annonc.2020.12.001
Volume 32, Issue 2, February 2021, Pages 282-283
Erratum to “Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”: Annals of Oncology 30; 2019: 1194–1220
F. Cardoso, S. Kyriakides, S. Ohno, F. Penault-Llorca, ... E. Senkus
doi : 10.1016/j.annonc.2020.08.2158
Volume 32, Issue 2, February 2021, Page 284
